Drug Trial Radar · NCT07318610
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
7,050
Planned (sponsor's estimate)
Start
Jul 10, 2026
Primary completion
Aug 18, 2029
Study completion Nov 16, 2029
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Jan 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching 2 different experimental drugs called REGN7508 and REGN9933. The study is focused on people who have Peripheral Artery Disease (PAD), which means that the blood vessels in their arms and legs have become too narrow. People with PAD have a higher risk of getting blood clots after procedures like Lower Extremity Revascularization (LER), a procedure to improve blood flow in the legs and feet. The aim of this study is to see how well REGN7508 and REGN9933 prevent life-threatening blood clots in participants with PAD who have recently had LER. The effects of REGN7508 and REGN9933, individually, will also be compared to rivaroxaban and a placebo. The study is looking at several other research questions, including: * What side effects might happen from taking the study drugs and how do they compare to the side effects of rivaroxaban * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the drugs less effective or could lead to side effects) * If the study drugs affect the ability of the blood to clot normally
Conditions
- Peripheral Artery Disease (PAD)
Interventions
REGN7508Drug
Administered per the protocol
REGN9933Drug
Administered per the protocol
PlaceboDrug
Administered per the protocol
RivaroxabanDrug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time-to-first occurrence of a major thrombotic vascular event, consisting of Acute Limb Ischemia (ALI), major amputation (above the ankle) of vascular etiology, Myocardial Infarction (MI), ischemic stroke, or Cardiovascular (CV) deathTime frame: Approximately up to 42 months
- Time-to-first occurrence of International Society of Thrombosis and Hemostasis (ISTH) major or Clinically Relevant Non-major (CRNM) bleedingTime frame: Approximately up to 42 months
Locations
34 sites in 3 countries. Site status is shown where the registry gives one.
Advanced Cardiovascular
Alexander City, Alabama · Recruiting
Lake Martin Medical and Vascular Center
Alexander City, Alabama · Recruiting
Axsendo Clinical Research, Integrated Medical Services
Avondale, Arizona · Recruiting
Applied Research Center of Arkansas
Little Rock, Arkansas · Recruiting
Angel City Research, Inc.
Los Angeles, California · Recruiting
Pacific Cardiovascular and Vein Institute
Oxnard, California · Recruiting
Interventional Cardiology Medical Group
West Hills, California · Recruiting
Nature Coast Clinical Research - Cardiology
Crystal River, Florida · Recruiting
University of Florida (UF) Health Jacksonville Clinical Center
Jacksonville, Florida · Recruiting
Inpatient Research Clinic LLC
Miami Lakes, Florida · Recruiting
Cardiovascular Institute of Northwest Florida, Main Office
Panama City, Florida · Recruiting
Tampa Cardiovascular Interventions and Research
Tampa, Florida · Recruiting
Lutheran Medical Group LLC dba Lutheran Health Physicians
Fort Wayne, Indiana · Recruiting
ASHA Clinical Research Munster, LLC
Hammond, Indiana · Recruiting
Profound Research, Powers Health Medical Group
Munster, Indiana · Recruiting
Cardiovascular Solutions
Shreveport, Louisiana · Recruiting
Rovia Clinical Research - Hattiesburg Clinic
Petal, Mississippi · Recruiting
Advanced Heart and Vascular Institute of Hunterdon
Flemington, New Jersey · Recruiting
Westchester Medical Center
Valhalla, New York · Recruiting
Mecklenburg Heart Specialists Vascular Institute and Vein Center
Charlotte, North Carolina · Recruiting
Accellacare of Piedmont, Piedmont Healthcare
Mooresville, North Carolina · Recruiting
Hightower Clinical
Oklahoma City, Oklahoma · Recruiting
Monument Health Clinical Research
Rapid City, South Dakota · Recruiting
Apex Research Foundation, LLC
Jackson, Tennessee · Recruiting
Tennova TCMC
Knoxville, Tennessee · Recruiting
Vanderbilt Heart and Vascular Tullahoma, Cardiology and Vascular Associates
Tullahoma, Tennessee · Recruiting
PharmaTex Research
Amarillo, Texas · Recruiting
Vital Heart and Vein
Cypress, Texas · Recruiting
Epic Medical Research
DeSoto, Texas · Recruiting
Epic Medical Research-Plano
Plano, Texas · Recruiting
Kita Harima Medical Center
Ono-shi, Hyōgo, Japan · Recruiting
Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust
Doncaster, United Kingdom · Recruiting
Charing Cross Hospital
London, United Kingdom · Recruiting
Manchester Royal Infirmary
Manchester, Greater Manchester, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.